Pharma Focus Asia

Perrigo Company Completes Divestiture Of API Business For $110 Million

Wednesday, November 22, 2017

Perrigo Company plc announced that it has completed the previously announced divestiture of its Active Pharmaceutical Ingredient (API) business based in Israel to SK Capital for $110 million.

Perrigo's CEO John T. Hendrickson stated, "Today's announcement furthers the strategic review process announced when I became CEO. Actions taken as part of this review process have enabled us to simplify, focus and execute on our core businesses. We continue to look at capital deployment opportunities that drive value for shareholders and further our mission of providing Quality, Affordable Healthcare Products® to consumers around the globe."

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Asia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024
Charles river - Endosafe Trillium